A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder

Journal of Urology

Volumn 149, Issue 4, 1993, Pages 749-752

  Oosterlinck, W ^a   Kurth, K H ^a   Schroder, F ^a   Bultinck, J ^a   Hammond, B ^a   Sylvester, R ^a   Boeken Kruger, C ^a   Van Aubel, D ^a   Newling, D ^a   Karthaus, P ^a   De Voogt, H ^a   Debruyne, F ^a   De Wall, J ^a   Janknegt, R A ^a   Langemeijer, T ^a   Van der Meijden, A ^a   Hoekstra, J ^a   Marechal, J M ^a   Vallancien, G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

bladder neoplasms; carcinoma, transitional cell; epirubicin

Indexed keywords

EPIRUBICIN;

ARTICLE; BLADDER CARCINOMA; BLADDER IRRITATION; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CYSTOSCOPY; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RECURRENCE RISK; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 0027506241     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(17)36198-0     Document Type: Article

References (17)

1. K.G. Burnand P.J.R. Boyd M.E. Mayo K.E.D. Shuttleworth R.W. Lloyd-Davies Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma Brit. J. Urol. 48 1976 55
2. P.H. Abrams R.G. Choa C.G.C. Gaches M.H. Ashken N.A. Green A controlled trial of single dose intravesical Adri-amycin in superficial bladder tumours Brit. J. Urol. 53 1981 585
3. H. Zincke D.C. Utz W.F. Taylor R.P. Myers F.J. Leary Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial J. Urol. 129 1983 505
4. K.H. Kurth P.A. Maksimović W.C.J. Hop F.H. Schröder N.J. Bakker Single-dose intravesical epodyl after TUR of Ta TCC bladder carcinoma World J. Urol. 1 1983 89
5. M.S. Soloway C. Martino Prophylaxis of bladder tumor implantation: intravesical and systemic chemotherapy Urology 7 1976 29
6. O. Dalesio C.C. Schulman R. Sylvester M. De Pauw M. Robinson L. Denis P. Smith G. Viggiano Members of the European Organization for Research on Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group: Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group J. Urol. 129 1983 730
7. K.H. Kurth F.H. Schröder U. Tunn R. Ay M. Pavone-Macaluso F. Debruyne M. de Pauw O. Dalesio F. ten Kate Members of the European Organization for Research on Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group: Adjuvant chemotherapy of superficial transitional cell bladder cancer: preliminary results of a European Organization for Research on Treatment of Cancer randomized trial comparing doxorubicin, hydrochloride, ethoglucid and transurethral resection alone J. Urol. 132 1984 258
8. F. Ganzina 4’-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data Cancer Treat. Rev. 10 1983 1
9. P. Hurteloup P. Cappelaere J.P. Armand G. Mathé Phase II clinical evaluation of 4’-epi-doxorubicin Cancer Treat. Rep. 67 1983 337
10. F. Calais da Silva L. Denis A. Bono C. Bollack C. Bouffioux Intravesical chemoresection with 4’-epi-doxorubicin in patients with superficial bladder tumors Eur. Urol. 14 1988 207
11. K.H. Kurth K. Mross F. Ten Kate G. Weiseglas P.J. Carpentier C.G.D. Boeken Krueger J. Blom J.M. Croen R.D. van Caubergh O. van Aube I. van Reyswoud Phase I/II study of intravesical epirubicin in patients with carcinoma in situ of the bladder In: Uro-Oncology: Current Status and Future Trends 1990 Wiley-Liss New York 41
12. D. Newling Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group Brit. J. Cancer 61 1990 497
13. K.H. Kurth C. Bouffioux R. Sylvester M. de Pauw Members of the EORTC GU-group: Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder Prog. Clin. Biol. Res. 269 1988 525
14. FDA requirements for approval of drugs to treat superficial bladder cancer. Transcript of Oncology Drugs Advisory Committee meeting on December 19 1988
15. Selvaggi, F. P., De Micheli, P., Pamparana, F. and Sacchetti, G.: Epirubicina endovescicale nella profilassi dei tumori superficiali della vescica. Studio Multicentrico, randomizzato. In: Proceedings of the XXXVIII Convegno della Societa di Urologia deiritalia Abstracts, Lecce, June 9-10, 1989.
16. D.A. Tolley T.B. Hargreave P.H. Smith J.L. Williams K.M. Grigor M.K.B. Parmar L.S. Freedman B.M. Uscinska Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working on Superficial Bladder Cancer (Urological Cancer Working Party) Brit. Med. J. 296 1988 1759
17. K. Kurth F.H. Schroeder F. Debruyne T. Senge M. Pavone-Macaluso M. de Pauw F. ten Kate R. Sylvester Members of the EORTC GU group: Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone Prog. Clin. Biol. Res. 303 1989 481